Eye-Catching Stock to Track: Predictive Oncology Inc (NASDAQ: POAI)

On Friday, Predictive Oncology Inc (NASDAQ: POAI) stock fell -5.76% and closed at 3.85. Its recent trading capacity is 38491 shares versus to its average trading volume of 28129 shares. The company stock lowest price point for the session stood at $3.78. POAI traded as low as $ 3.32 in the past 52 weeks, and shares hit its peak level to $11.5.

Financial Results

Revenue for the quarter ended September 30, 2019 was $522,696 contrast with $329,930 for the same period of 2018, a 58 percent increase year over year. Revenue included the sale of 19 STREAMWAY systems and disposable supplies, contrast to 10 sales of the system in the comparable period of 2018. Cost of sales was $208,096 in the third quarter of 2019, contrast to $83,006 in Q3 2018. Gross profit margin declined to 60% percent versus 75% in the third quarters of 2019 and 2018 respectively. Operating expenses for the quarter ended September 30, 2019 declined to $707,414 contrast to $723,939 for the third quarter of 2018. General and administrative expenses were $2,616,991, contrast to $762,603 during the same period of the previous year. Sales and marketing expenses also declined to $434,955 in Q3 2019 contrast to $621,465 for the previous year.

Dr. Carl Schwartz, the Company’s Chief Executive Officer commented, “I am very happy with the growth and development of our exclusive assets, Helomics and Tumor Genesis, and the and the increase in international interest in our Skyline products. The future looks very bright.”

Predictive Oncology Inc., (POAI) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services reported financial results for the quarter ended September 30, 2019 and provided a business update.

POAI has a gross margin of 67.70%. Its earnings per share (EPS) expected to touch remained 16.60% for this year. According to the most recent quarter its current ratio was 0.1 that represents company’s ability to meet its current financial obligations. The price moved ahead of -8.16% from the mean of 20 days, -17.71% from mean of 50 days SMA and performed -40.86% from mean of 200 days price. Company’s performance for the week was -10.58%, -12.61% for month and YTD performance remained -37.90%.


Leave a Reply

Your email address will not be published. Required fields are marked *